Asian Spectator

.
Business Advice

.

Shineway (2877.HK) Q1 revenue increased by 37.0%

  • Written by ACN Newswire - Press Releases

Shineway (2877.HK) Q1 revenue increased by 37.0%

HONG KONG, May 13, 2021 - (ACN Newswire) - China Shineway Pharmaceutical Group Limited (2877.HK) recently released its unaudited turnover for the three months ended 31 March 2021 (Q1 2021) based on its management accounts.

Revenue for Q1 2021 went up 37.0% YoY, which implies a growth of 20.4% over the pre-COVID 19 levels, as compared with the same period of 2019. The Group's main product types all achieved significant growth. Sales of injection products went up by 34.2%; soft capsule products recorded growth of 6.6%; granule products showcased the strongest turnover growth of 62.2%; turnover of TCM formula granule products increased by 50.5%. For products in other forms, turnover grew by 54.2%.

FINET News H.K.http://www.shineway.com.hk/en/index.aspx

Copyright 2021 ACN Newswire. All rights reserved. www.acnnewswire.com

Authors: ACN Newswire - Press Releases

Read more //?#

Magazine

Akankah kamu bahagia jika lama melajang? Jawabannya tergantung gaya keterikatanmu

Marvin / ShutterstockApakah semua orang lajang merasa insecure? Ketika kita berpikir tentang orang-orang yang sudah lama melajang, kita mungkin berasumsi bahwa itu karena para lajang tersebut memiliki...

Jalan hantu: riset kami tunjukkan luasnya jalan ilegal yang membabat hutan Indonesia

Ilmuwan ternama asal Brasil, Eneas Salati, pernah mengatakan, “Yang terbaik yang bisa kamu lakukan untuk hutan hujan Amazon adalah meledakkan jalan-jalan.”Eneas tidak bercanda. Dia ada ben...

Melihat lebih dekat praktik berladang ramah lingkungan “Gilir Balik” masyarakat Ngaung Keruh (bagian 2)

Ladang Gilir Balik di antara rimbunan hutan dan kebun wanatani. Semuanya menjadi mozaik bentang alam yang turut menjaga kelestarian daerah tangkapan air Danau Sentarum.(Rifky/CIFOR), CC BY-NCBagian pe...



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion